Find Clinical Trial

Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of choroidal neovascularisation in age-related macular degeneration: a multicentre, randomised, double-blind, placebo-controlled, phase III study in 1100 patients treated for 3 to 5 years


← Back
Study Phase Phase 3
Therapeutic Area Cardiovascular
Active Substance TRIMETAZIDINE
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS006790
Protocol CodeMC3-06790-001
ISRCTN CodeISRCTN99532788


Documents and links

Results summary READ MORE



Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.